Dementia Support Line
Delivering drugs
From our winter 2016 issue of Care and Cure magazine, find out more about research in mice that raises the possibility of a new treatment delivered by nasal spray.
Researchers have developed a new treatment that could block the development of Alzheimer’s disease by using microscopic droplets of fat to carry drugs into the brain. This approach, used to target drugs to cancer cells, has been successfully applied to Alzheimer’s for the first time, restoring memory loss in mice.
The study was led by researchers at Lancaster University, funded by Alzheimer’s Society, and was published in the journal Nanomedicine: Nanotechnology, Biology and Medicine.
The treatment uses tiny droplets of fat, called nanoliposomes, which are coated in protein fragments. These fragments are able to stop amyloid protein accumulating into plaques, even at low concentrations. Amyloid plaques are the toxic clumps of protein that cause damage to cells in the brains of people with Alzheimer’s disease.
Lead researcher Professor David Allsop said, 'Following results this summer, there is renewed optimism for antibody drugs – treatments that harness the body’s immune system to target amyloid plaques. However if these prove successful, treatments will have to be administered in a clinic by an IV drip and could have some potentially harmful side effects.’
Nanoliposomes are already used to better target toxic chemotherapy drugs to cancer cells. Recent studies have also shown that the fat droplets can pass directly into the brain through the nose, opening up the possibility of using a nasal spray to administer treatments for brain diseases, such as Alzheimer’s.
Professor Allsop said, 'Using nanoliposomes offers an alternative way to inhibit the toxic build-up of amyloid plaques without activating an immune response in the brain. Our hope is that this could one day be administered by something as simple and non-invasive as a nasal spray, which patients could use in the comfort of their own home.'
Mice that were genetically altered to develop Alzheimer’s disease were injected with the nanoliposomes for three weeks. Those which received the drug recovered their long-term memory and could recognise familiar objects after a 24-hour period. In comparison, mice that received a placebo injection had no memory of objects seen the day before.
Commenting on the need for innovative approaches to dementia treatments, Dr Doug Brown, Director of Research and Development at Alzheimer’s Society, said, 'With no new dementia drugs in nearly 15 years, we’re at a critical time for dementia research. It’s absolutely vital that we continue to sniff out new approaches to getting drugs into the brain.
‘While we wait in anticipation for the results of ongoing clinical trials, Alzheimer’s Society will continue to fund innovative research to tackle dementia head on.'
